Propargylamine containing ompounds as modulators of proteolytic cleavage of amyloid protein precursor: Involvement of MAPK and PKC activation

Journal of Alzheimer's Disease

Volumn 21, Issue 2, 2010, Pages 361-371

  Bar Am, Orit ^a   Amit, Tamar ^a   Weinreb, Orly ^a   Youdim, Moussa B H ^a   Mandel, Silvia ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Alzheimer's disease; amyloid peptide; amyloid protein precursor (A PP); mitogen activated protein kinase (MAPK); multifunctional drugs; propargylamine derivatives; protein kinase C (PKC); sA PP

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 5 [(N METHYL N PROPARGYLAMINOMETHYL) 8 HYDROXYQUINOLINE]; AMYLOID PRECURSOR PROTEIN; ANTIPARKINSON AGENT; DEFEROXAMINE; DONEPEZIL; LADOSTIGIL; MITOGEN ACTIVATED PROTEIN KINASE; MONOAMINE OXIDASE INHIBITOR; PROTEIN KINASE C; RASAGILINE; RIVASTIGMINE; SELEGILINE; TVP 3279; UNCLASSIFIED DRUG; VK 28; AMYLOID BETA PROTEIN; DRUG DERIVATIVE; PARGYLINE; PROPARGYLAMINE; PROPYLAMINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; LEWY BODY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; ANIMAL; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PARGYLINE; PROPYLAMINES; PROTEIN KINASE C;

EID: 77957374286     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100150     Document Type: Review

References (83)

1. Tabakman R, Lecht S and Lazarovici P (2003) Neuroprotection by monoamine oxidase B inhibitors: A therapeutic strategy for Parkinson's disease? Bioessays 26, 8090.
2. Naoi M and Maruyama W (2009) Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother 9, 12331250.
3. Chen JJ, Swope DMand Dashtipour K (2007) Comprehensive review of rasagiline, a secondgeneration monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 29, 18251849.
4. Shahani N, GourieDevi M, Nalini A, Rammohan P, Shobha K, Harsha HN and Raju TR (2004) () Deprenyl alleviates the degenerative changes induced in the neonatal rat spinal cord by CSF from amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Other Motor Neuron Disord 5, 172179.
5. Mandel S,Weinreb O, Amit T and Youdim MB (2005) Mechanism of neuroprotective action of the antiParkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 48, 379387.
6. BarAm O, Weinreb O, Amit T and Youdim MB (2005) Regulation of Bcl2 family proteins, neurotrophic factors, and AβPP processing in the neurorescue activity of propargylamine. FASEB J 19, 18991901.
7. Weinreb O, BarAm O,Amit T, ChillagTalmor O and Youdim MBH (2004) Neuroprotection via prosurvival protein kinase C isoforms associated with Bcl2 family members. FASEB J 18, 14711473.
8. Sagi Y, Mandel S, Amit T and Youdim MB (2007) Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in postMPTPinduced parkinsonism. Neurobiol Dis 25, 3544.
9. Nakaso K, Nakamura C, Sato H, Imamura K, Takeshima T and Nakashima K (2006) Novel cytoprotective mechanism of antiparkinsonian drug deprenyl: PI3K and Nrf2derived induction of antioxidative proteins. Biochem Biophys Res Commun 339, 915922.
10. BarAm O, YogevFalach M, Amit T, Sagi Y and Youdim MBH (2004) Regulation of protein kinase C by the antiParkinson drug, MAOB inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 89, 11191125.
11. Zheng H,Weiner LM, BarAm O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB and Fridkin M (2005) Design, synthesis, and evaluation of novel bifunctional ironchelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem 13, 773783.
12. Gal S, Zheng H, Fridkin M and Youdim MB (2005) Novel multifunctional neuroprotective iron chelatormonoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTPinduced striatal dopamine depletion. J Neurochem 95, 7988.
13. Zecca L, M.B.H. y, Riederer P and Connor JA (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5, 863873.
14. BarAm O, Weinreb O, Amit T and Youdim MB (2009) The novel cholinesterasemonoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J Mol Neurosci 37, 135145.
15. Weinstock M, Poltyrev T, Bejar C and youdim MBH (2002) Effect of TV3326, a novel monoamineoxidase cholinesterase inhibitor, in ratmodels of anxiety and depression. Psychopharmacology (Berl) 160, 318324.
16. WeinstockM, BejarC,WangRH, Poltyrev T,GrossA, Finberg J and Youdim MBH (2000) TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J Neural Transm suppl 60, S157S170.
17. Weinstock M, KirschbaumSlager N, Lazarovici P, Bejar C, Youdim MBH and Shoham S (2001) Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential antiAlzheimer drugs. Ann N Y Acad Sci 939, 148161.
18. AvramovichTirosh Y, Amit T, Bar Am O, Zheng H, Fridkin M and Youdim M (2006) Therapeutic targets and potential of the novel brainpermeable multifunctional iron chelator- monoamine oxidase inhbitor drug, M30, for the treatment of Alzheimer's disease. J Neurochem 100, 490502.
19. Weinreb O, Amit T, BarAm O, YogevFalach M and Youdim MB (2008) The neuroprotective mechanism of action of the multimodal drug ladostigil. Front Biosci 13, 51315137.
20. Weinreb O, BarAmO, Amit T,Drigues N, Sagi Yand Youdim MB (2008) The neuroprotective effect of ladostigil against hydrogen peroxidemediated cytotoxicity. Chem Biol Interact 175, 318326.
21. Van der Schyf CJ, Mandel S, Geldenhuys WJ, Amit T, Avramovich Y, Zheng H, Fridkin M, Gal S, Weinreb O, Bar Am O, Sagi Y and Youdim MB (2007) Novel multifunctional antiAlzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties. Curr Alzheimer Res 4, 522536.
22. Kupershmidt L,Weinreb O, Amit T, Mandel S, Carri MT and Youdim MB (2009) Neuroprotective and neuritogenic activities of novelmultimodal ironchelating drugs inmotorneuronlike NSC34 cells and transgenic mousemodel of amyotrophic lateral sclerosis. FASEB J 23, 37663779.
23. Vetrivel KS and Thinakaran G(2006) Amyloidogenic processing of betaamyloid precursor protein in intracellular compartments. Neurology 66, S69S73.
24. Yang HQ, Ba MW, Ren RJ, Zhang YH, Ma JF, Pan J, Lu GQ and Chen SD (2007) Mitogen activated protein kinase and protein kinase C activation mediate promotion of sAβPPalpha secretion by deprenyl. Neurochem Int 50, 7482.
25. Yang HQ, Sun ZK, Ba MW, Xu J and Xing Y (2009) Involvement of protein trafficking in deprenylinduced alphasecretase activity regulation in PC12 cells. Eur J Pharmacol 610, 3741.
26. YogevFalachM, Amit T, BarAmO, SagiY,WeinstockMand Youdim MBH (2002) The involvement of mitogenactivated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 16, 16741676.
27. YogevFalach M, Amit T, BarAM O and Youdim MBH (2003) The importance of propargylamine moiety in the antiParkinson drug rasagiline and its derivatives for MAPKdependent amyloid precursor protein processing. FASEB J 17, 23252327.
28. Zhang YW and Xu H (2007) Molecular and cellular mechanisms for Alzheimer's disease: Understanding AβPP metabolism. Curr Mol Med 7, 687696.
29. Nitsch RM, Slack BE, Wurtman RJ and Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation ofmuscarinic acetylcholine receptors. Science 258, 304307.
30. Buxbaum JD, Oishi M, Chen HI, PinkasKramarski R, Jaffe EA, Gandy SE and Greengard P (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci U S A 89, 1007510078.
31. Giacobini E, Mori F and Lai CC (1996) The effect of cholinesterase inhibitors on the secretion of APPS from rat brain cortex. Ann N Y Acad Sci 777, 393398.
32. Mori F, Lai C, Fusi F and Giacobini E (1995) Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 6, 633636.
33. Nitsch RM, Slack BE, Farber SA, Borghesani PR, Schulz JG, Kim C, Felder CC, Growdon JH and Wurtman RJ (1993) Receptorcoupled amyloid precursor protein processing. Ann N Y Acad Sci 695, 122127.
34. DavisSalinas J, SaporitoIrwin SM, Donovan FM, Cunningham DD and Van Nostrand WE (1994) Thrombin receptor activation induces secretion and nonamyloidogenic processing of amyloid betaprotein precursor. J Biol Chem 269, 2262322627.
35. Lee RK,Wurtman RJ, Cox AJ and Nitsch RM(1995)Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci U S A 92, 80838087.
36. Nitsch RM, Deng M, Growdon JH and Wurtman RJ (1996) Serotonin 5HT2a and 5HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem 271, 41884194.
37. Chen Y and Tang BL (2006) The amyloid precursor protein and postnatal neurogenesis/neuroregeneration. Biochem Biophys Res Commun 341, 15.
38. Hampel H, Shen Y,Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ and Blennow K (2010) Biological markers of amyloid betarelated mechanisms in Alzheimer's disease. Exp Neurol 223, 334346.
39. Chow VW,Mattson MP,Wong PC and Gleichmann M (2010) An overview of AβPP processing enzymes and products. Neuromolecular Med 12, 112.
40. Mills J and Reiner PB (1999) Regulation of amyloid precursor protein cleavage. J Neurochem 72, 443460.
41. Lanni C,Mazzucchelli M, Porrello E, Govoni S and Racchi M (2004) Differential involvement of protein kinase C alpha and epsilon in the regulated secretion of soluble amyloid precursor protein. Eur J Biochem 271, 30683075.
42. Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman RJ, Growdon JH and Selkoe DJ (1993) Activation of protein kinase C inhibits cellular production of the amyloid betaprotein. J Bio Chem 268, 2295922962.
43. Kim SK, Park HJ, Hong HS, Baik EJ, Jung MW and MookJung I (2006) ERK1/2 is an endogenous negative regulator of the gammasecretase activity. FASEB J 20, 157159.
44. Mills J, LaurentCharestD, LamF, BeyreutherK, IdaN, Pelech SL andReiner PB(1997)Regulation of amyloid precursor protein catabolism involves the mitogenactivated protein kinase signal transduction pathway. J Neurosci 17, 94159422.
45. DesdouitsMagnen J, Desdouits F, Takeda S, Syu LJ, Saltiel AR, Buxbaum JD, Czernik AJ, Nairn AC and Greengard P (1998) Regulation of secretion of Alzheimer amyloid precursor protein by the mitogenactivated protein kinase cascade. J Neurochem 70, 524530.
46. Origlia N, Arancio O, Domenici L and Yan SS (2009)MAPK, betaamyloid and synaptic dysfunction: The role of RAGE. Expert Rev Neurother 9, 16351645.
47. Takuma K, Fang F, Zhang W, Yan S, Fukuzaki E, Du H, Sosunov A,McKhann G, Funatsu Y, Nakamichi N, Nagai T,Mizoguchi H, Ibi D, Hori O, Ogawa S, Stern DM, Yamada K and Yan SS (2009) RAGEmediated signaling contributes to intraneuronal transport of amyloidbeta and neuronal dysfunction. Proc Natl Acad Sci U S A 106, 2002120026.
48. Birkmayer Wand Birkmayer GD (1986) Effect of (-) deprenyl in longterm treatment of Parkinson's disease. A 10years experience. J Neural Transm Suppl 22, 219225.
49. Ebadi M, Sharma S, Shavali S and El Refaey H (2002) Neuroprotective actions of selegiline. J Neurosci Res 67, 285289.
50. Filip V and Kolibas E (1999) Selegiline in the treatment of Alzheimer's disease: A longterm randomized placebocontrolled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J Psychiatry Neurosci 24, 234243.
51. Birks J and Flicker L (2003) Selegiline for Alzheimer's disease. Cochrane Database Syst Rev, CD000442.
52. Brandeis R, Sapir M, Kapon Y, Borelli G, Cadel S and Valsecchi B (1991) Improvement of cognitive function by MAOB inhibitor Ldeprenyl in aged rats. Pharmacol Biochem Behav 39, 297304.
53. Tariot PN, Cohen RM, Sunderland T, Newhouse PA, Yount D, Mellow AM, Weingartner H, Mueller EA and Murphy DL (1987) Ldeprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 44, 427433.
54. Tsunekawa H, Noda Y, Mouri A, Yoneda F and Nabeshima T (2008) Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (2535). Behav Brain Res 190, 224232.
55. Ono K, Hasegawa K, Naiki H and Yamada M (2006) AntiParkinsonian agents have antiamyloidogenic activity for Alzheimer's betaamyloid fibrils in vitro. Neurochem Int 48, 275285.
56. Hu MK, Liao YF, Chen JF, Wang BJ, Tung YT, Lin HC and LeeKP (2008)New1,2,3,4tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins. Bioorg Med Chem 16, 19571965.
57. Chen JJ and Swope DM (2005) Clinical pharmacology of rasagiline: A novel, secondgeneration propargylamine for the treatment of Parkinson disease. JClin Pharmacol 45, 878894.
58. Sterling J, Veinberg A, Lerner D, Goldenberg W, Levy R, Youdim M and Finberg J (1998) (R)(+)Npropargyl1aminoindan (rasagiline) and derivatives: Highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl 52, 301305.
59. Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE and Mattevi A (2005) Binding of rasagilinerelated inhibitors to human monoamine oxidases: A kinetic and crystallographic analysis. J Med Chem 48, 81488154.
60. Finberg JPM, Tenne M and Youdim MBH (1981) Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. InMonoamine oxidase inhibitors - the state of the art, YoudimMBH, Peykel ES, eds. Wiley, Chichester, pp. 3141.
61. Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ and Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6, 542544.
62. Yoshida T, Yamada Y, Yamamoto T and Kuroiwa Y (1986) Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: Relationship ofmetabolism toMAOB inhibitory potency. Xenobiotica 16, 129136.
63. Youdim MB, Bar Am O, YogevFalach M, Weinreb O, Maruyama W, Naoi M and Amit T (2005) Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79, 172179.
64. Blandini F (2005) Neuroprotection by rasagiline: A new therapeutic approach to Parkinson's disease? CNS Drug Rev 11, 183194.
65. Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, PoeweW, Tolosa E, Stocchi F,Melamed E, Eyal E and Rascol O (2008) A randomized, doubleblind, placebocontrolled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (theADAGIOstudy): Rationale, design, and baseline characteristics. Mov Disord 23, 21942201.
66. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F and Tolosa E (2009) A doubleblind, delayedstart trial of rasagiline in Parkinson's disease. N Engl J Med 361, 12681278.
67. Weinstock M, Goren T and Youdim MBH (2000) Development of a novel neuroprotective drug (TV3326) for the treatment of alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev Res 50, 216222.
68. Youdim MB, Amit T, BarAm O, Weinreb O and YogevFalachM( 2006) Implications of comorbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotectiveneurorescue drugs; ladostigil. Neurotox Res 10, 181192.
69. YoudimMB and Buccafusco JJ (2005) Multifunctional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26, 2735.
70. Sagi Y,Weinstock Mand YoudimMBH (2003) Attenuation of MPTPInduced Dopaminergic Neurotoxicity by TV3326, A cholinesterasemonoamine oxidase inhibitor. Journal of Neurochemistry 2, 290297.
71. Weinstock M, Gorodetsky E, Wang RH, Gross A, Weinreb O and Youdim MBH (2002) Limited potentiation of blood pressure response to oral tyramine by brainselective monoamine oxidase AB inhibitor, TV3326 in conscious rabbits(1). Neuropharmacology 43, 9991005.
72. Shoham S, Bejar C, Kovalev E, SchorerApelbaum D and Weinstock M (2007) Ladostigil prevents gliosis, oxidativenitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. Neuropharmacology 52, 836843.
73. Weinstock M, Luques L, Poltyrev T, Bejar C and Shoham S (2009) Ladostigil prevents agerelated glial activation and spatial memory deficits in rats. Neurobiol Aging, doi:10.1016/j.neurobiolaging.2009.06.004.
74. Weinstock M, Poltyrev T, Bejar C, Sagi Y and Youdim MBH (2002) TV3326, a novel cholinesterase and MAO inhibitor for Alzheimer's disease with comorbidity of Parkinson's disease and depression. In Mapping the progress of Alzheimer's and Parkinson's disease,Mizuno Y, FisherA, Hanin I, eds. Kluwer Academic/Plenum Publishers, New York, pp. 199204.
75. Youdim MBH, Wadia A, Tatton NA and Weinstock M (2001) The antiParkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated toMAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 939, 450458.
76. Youdim MBH and Weinstock M (2002) Molecular basis of neuroprotective activities of rasagiline and the anti alzheimer drug, TV3326, [(NPropargyl( 3R)Aminoindan5YL) Ethyl Methyl Carbamate]. Cell Mol Neurobiol 21, 555573.
77. YogevFalach M, BarAm O, Amit T,Weinreb O and Youdim MB (2006) Amultifunctional, neuroprotective drug, ladostigil (TV3326), regulates holoA βPP translation and processing. FASEB J 20, 21772179.
78. Amit T, AvramovichTirosh Y, Youdim MB and Mandel S (2008) Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J 22, 12961305.
79. Zheng H, Gal S, Weiner LM, BarAm O, Warshawsky A, Fridkin M and Youdim MB (2005) Novel multifunctional neuroprotective iron chelatormonoamine oxidase inhibitor drugs for neurodegenerative diseases: In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95, 6878.
80. AvramovichTirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, Mandel S and Youdim MB (2007) Neurorescue activity, AβPP regulation and amyloidbeta peptide reduction by novel multifunctional brain permeable ironchelatingantioxidants, M30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4, 403411.
81. AvramovichTirosh Y, BarAm O, Amit T, Youdim MB and Weinreb O (2009) Upregulation of hypoxiainducible factor (HIF)1alpha and HIFtarget genes in cortical neurons by the novelmultifunctional iron chelator antiAlzheimer drug,M30. Curr Alzheimer Res 7(4), 300306.
82. Rogers JT and Lahiri DK (2004) Metal and inflammatory targets forAlzheimer's disease. Curr Drug Targets 5, 535551.
83. Rogers JT,Randall JD,CahillCM, Eder PS,HuangX,Gunshin H, Leiter L,McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, TanziRE,BushAI,GiordanoT andGullans SR(2002)An ironresponsive element type II in the 5'untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277, 4551845528.